A nightmare for haematology clinics: Extensively drug-resistant (xdr) acinetobacter baumannnii;Acinetobacter baumannii xdr: Un incubo per i reparti di ematologia

Infezioni in Medicina

Volumn 22, Issue 4, 2014, Pages 277-282

  Metan, Gökhan ^a   Pala, Çiǧdem ^b   Kaynar, Leylagül ^b   Cevahir, Fatma ^c   Alp, Emine ^a,c  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Department of Haematology ^*  (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; Bacteraemia; Febrile neutropenia; Haematological malignancy; XDR

Indexed keywords

AMIKACIN; CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; COLISTIN; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL TRANSPLANTATION; CLINICAL ARTICLE; DEATH; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII; FEMALE; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HOSPITAL PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; MALE; MORTALITY; MYELOID LEUKEMIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; REMISSION; ACINETOBACTER INFECTIONS; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEMATOLOGY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE; TEACHING HOSPITAL; TREATMENT OUTCOME; TURKEY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGY; HOSPITALS, TEACHING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SULBACTAM; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY;

EID: 84920410186     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Metan G., Sariguzel F., Sumerkan B., Reijden T., Dijkshoorn L. Clonal diversity and high prevalence of OXA-58 among Acinetobacter baumannii isolates from blood cultures in a tertiary care centre in Turkey. Infect. Genet. Evol. 14, 92-97, 2013.
2. Alp E., Kiran B., Altun D., et al. Changing pattern of antibiotic susceptibility in intensive care units: ten years experience of a university hospital. Anaerobe 17, 422-425, 2011.
3. Metan G., Demiraslan H., Kaynar L.G., Zararsız G., Alp E., Eser B. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz. J. Infect. Dis. 17, 143-149, 2013.
4. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health careassociated infection and criteria for specific types of infections inthe acute care setting. Am. J. Infect. Control 36, 309-332, 2008.
5. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813-1821, 2008.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-First Informational Supplement. CLSI Document M100-S21. CLSI, Wayne, PA, 2011.
7. Liu J.W., Ko W.C., Huang C.H., et al. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. Antimicrob. Agents. Chemother. 56, 1414-1417, 2012.
8. Magiorakos A.P., Srinivasan A., Carey R.B., et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim Standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268-281, 2012.
9. Bow E.J. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J. Antimicrob. Chemother. 68, 492-495, 2013.
10. Metan G., Alp E., Yildiz O., Percin D., Aygen B., Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J. Chemother. 22, 110-114, 2010.
11. Shields R.K., Clancy C.J., Gillis L.M., et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7(12), e52349, 2012.
12. Hugonnet S., Chevrolet J.C., Pittet D. The effect of workload on infection risk in critically ill patients. Crit. Care Med. 35, 76-81, 2007.